```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01   INPADOC: New family current-awareness alert (SDI) available
 NEWS  4  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS  5  SEP 01   New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS  6  SEP 27   STANDARDS will no longer be available on STN
 NEWS  7  SEP 27   SWETSCAN will no longer be available on STN
 NEWS  8  OCT 28   KOREAPAT now available on STN
 NEWS  9  NOV 18   Current-awareness alerts, saved answer sets, and current
                   search transcripts to be affected by CERAB, COMPUAB, ELCOM,
                   and SOLIDSTATE reloads
 NEWS 10  NOV 30   PHAR reloaded with additional data
 NEWS 11  DEC 01   LISA now available on STN

 NEWS EXPRESS  OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:35:32 ON 03 DEC 2004

=> file caplus uspatful europatful japio medline biosis embase scisearch
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILE 'CAPLUS' ENTERED AT 16:36:22 ON 03 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:36:22 ON 03 DEC 2004
```

```
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:36:22 ON 03 DEC 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:36:22 ON 03 DEC 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:36:22 ON 03 DEC 2004

FILE 'BIOSIS' ENTERED AT 16:36:22 ON 03 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 16:36:22 ON 03 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:36:22 ON 03 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

=> s ((cyclooxygenase 2 inhibitor?) or (Cox 2 inhibit?))
   3 FILES SEARCHED...
L1       23306 ((CYCLOOXYGENASE 2 INHIBITOR?) OR (COX 2 INHIBIT?))

=> s l1 and ((drug delivery) or pharmaceutical?)
   3 FILES SEARCHED...
L2        3175 L1 AND ((DRUG DELIVERY) OR PHARMACEUTICAL?)

=> s L2 and oral?
L3        2272 L2 AND ORAL?

=> s l3 and (particul? or particle?)
L4        2027 L3 AND (PARTICUL? OR PARTICLE?)

=> s l4 and (celecoxib or deracoxib or caldecoxib or rofecoxib)
L5         974 L4 AND (CELECOXIB OR DERACOXIB OR CALDECOXIB OR ROFECOXIB)

=> s l5 and (particle size) and (nanometer# or nm)
   6 FILES SEARCHED...
L6         112 L5 AND (PARTICLE SIZE) AND (NANOMETER# OR NM)

=> s l6 and (tablet# or capsule#)
L7         105 L6 AND (TABLET# OR CAPSULE#)

=> s l7 and (acute pain)
L8          16 L7 AND (ACUTE PAIN)

=>
=> d l8 1-16 ibib abs

L8   ANSWER 1 OF 16  USPATFULL on STN
ACCESSION NUMBER:       2004:291956  USPATFULL
TITLE:                  Nanoparticulate meloxicam formulations
INVENTOR(S):            Cooper, Eugene R., Berwyn, PA, UNITED STATES
                        Ryde, Tuula, Malvern, PA, UNITED STATES
                        Pruitt, John, Collegeville, PA, UNITED STATES
                        Kline, Laura, Harleysville, PA, UNITED STATES
PATENT ASSIGNEE(S):     Elan Pharma International Ltd. (U.S. corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2004229038      A1   20041118
APPLICATION INFO.:      US 2004-784900     A1   20040224  (10)

                              NUMBER        DATE
```

	NUMBER	KIND	DATE
PRIORITY INFORMATION:	US 2003-450705P		20030303 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2600

AB The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam **particles** of the composition have an effective average **particle size** of less than about 2000 **nm**.

L8 ANSWER 2 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:239305 USPATFULL
TITLE: Formulations of low solubility bioactive agents and processes for making the same
INVENTOR(S): Harland, Ronald, Yardley, PA, UNITED STATES
Wei, Chenkou, Princeton Junction, NJ, UNITED STATES
Kim, Soojin, West Orange, NJ, UNITED STATES
Hsieh, Alice Huey-Mei, Edison, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185110	A1	20040923
APPLICATION INFO.:	US 2003-701229	A1	20031104 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-424747P	20021108 (60)
	US 2002-433689P	20021216 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of coprocessing a limited solubility bioactive agent with a compatible aid comprising: (a) identifying a compatible aid for the bioactive agent; (b) either (i) forming a co-dissolved solution of the compatible aid and bioactive agent in a common solvent or (ii) forming a solution of the compatible aid in an anti-solvent and forming solution of the bioactive agent in a solvent; and (c) forming a film or primary **particles** from the co-dissolved solution or solutions of step (b), which film or primary **particles** comprise bioactive agent in crystalline form, with the crystals having average diameter of 1 micron or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:202983 USPATFULL
TITLE: Novel nimesulide compositions
INVENTOR(S): Bosch, H. William, Bryn Mawr, PA, UNITED STATES
Wertz, Christian F., Brookhaven, PA, UNITED STATES
PATENT ASSIGNEE(S): Elan Pharma International Ltd. (U.S. corporation)

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004156872	A1	20040812
APPLICATION INFO.:	US 2003-697703	A1	20031031 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-276400, filed on 15 Jan 2003, PENDING Continuation of Ser. No. US 2000-572961, filed on 18 May 2000, GRANTED, Pat. No. US 6316029
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
LINE COUNT: 2811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide **particles**. The nanoparticulate nimesulide **particles** preferably have an effective average **particle size** of less than about 2000 **nm**. The invention also provides methods of making and using nanoparticulate nimesulide compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:177826 USPATFULL
TITLE: Treatment of pain using TNFalpha inhibitors
INVENTOR(S): Banerjee, Subhashis, Shrewsbury, MA, UNITED STATES
Taylor, Lori K., Wadsworth, IL, UNITED STATES
Spiegler, Clive E., Reading, UNITED KINGDOM
Tracey, Daniel Edward, Harvard, MA, UNITED STATES
Chartash, Elliot K., Randolph, NJ, UNITED STATES
Hoffman, Rebecca S., Wilmette, IL, UNITED STATES
Barchuk, William T., Madison, NJ, UNITED STATES
Yan, Philip, Vernon Hills, IL, UNITED STATES
Murtaza, Anwar, Westborough, MA, UNITED STATES
Salfeld, Jochen G., North Grafton, NC, UNITED STATES
Fischkoff, Steven, Short Hills, NJ, UNITED STATES
PATENT ASSIGNEE(S): Abbott Biotechnology Ltd., Hamilton, BERMUDA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004136990	A1	20040715
APPLICATION INFO.:	US 2003-623035	A1	20030718 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-397275P	20020719 (60)
	US 2002-411081P	20020916 (60)
	US 2002-417490P	20021010 (60)
	US 2003-455777P	20030318 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, LLP., 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 2488
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating pain syndromes in which TNFα activity is detrimental are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:114794 USPATFULL
TITLE: Polymorphic crystalline forms of **celecoxib**
INVENTOR(S): Ferro, Leonard J., Highland Park, IL, UNITED STATES
Miyake, Patricia S., Tower Lakes, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004087640	A1	20040506	
APPLICATION INFO.:	US 2000-728040	A1	20001201	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169856P	19991209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: James M. Warner, Pharmacia Corporation, 800 N. Lindbergh/O4E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 175
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 2199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pharmaceutical** compositions are provided comprising one or more **orally** deliverable dose units, each comprising a selective **cyclooxygenase-2 inhibitory** compound of low water solubility in a therapeutically effective amount, wherein the compound is present in the form of solid **particles**, about 25% to 100% by weight of which are smaller than 1 mm. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have **particular** advantages where rapid onset of therapeutic effect is desired. The novel Form I and Form II crystalline forms of **celecoxib** are described. The crystalline forms have unique chemical and physical properties relative to other solid state forms of **celecoxib** and are characterized by their powder x-ray diffraction (PXRD) patterns, differential scanning calorimetric (DSC) thermograms, and other physical characterizations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:334720 USPATFULL
TITLE: Process for preparing a finely self-emulsifiable **pharmaceutical** composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
He, Xioarong, Portage, MI, UNITED STATES
Bolyard, Keith B., Otsego, MI, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235596	A1	20031225	
APPLICATION INFO.:	US 2003-408934	A1	20030407	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-371200P	20020409 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1
LINE COUNT: 2210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An **orally** deliverable **pharmaceutical** composition is provided comprising a drug of low water solubility and a solvent liquid that comprises at least one **pharmaceutically** acceptable solvent, at least one **pharmaceutically** acceptable fatty acid and at least one **pharmaceutically** acceptable organic amine, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the fatty acid and the organic amine are present in total and relative amounts such that the composition is finely self-emulsifiable in simulated gastric fluid. A process for preparing such a composition is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:195076 USPATFULL
TITLE: Use of a **celecoxib** composition for fast pain relief
INVENTOR(S): Karim, Aziz, Skokie, IL, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Gao, Ping, Portage, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134887	A1	20030717
APPLICATION INFO.:	US 2002-330946	A1	20021227 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-866165, filed on 25 May 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207729P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HARNESS, DICKEY, & PIERCE, P.L.C, 7700 BONHOMME, STE 400, ST. LOUIS, MO, 63105
NUMBER OF CLAIMS: 118
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1437
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises **orally** administering to the subject an effective pain-relieving amount of a composition comprising **celecoxib** formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of **celecoxib** in which a concentration of about 250 ng/ml is attained not later than about 30 minutes after **oral** administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:153476 USPATFULL
TITLE: Stabilized **oral pharmaceutical** composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Huang, Tiehua, Kalamazoo, MI, UNITED STATES

Robins, Russell H., Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
Guido, Jane E., Vicksburg, MI, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105144	A1	20030605
APPLICATION INFO.:	US 2002-119118	A1	20020409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284589P	20010417 (60)
	US 2002-357959P	20020219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Patent Department, 800 N. Lindbergh Boulevard-04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 2152
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An **orally** deliverable **pharmaceutical** composition is provided comprising an aminosulfonyl-comprising drug, for example a selective **cyclooxygenase-2 inhibitory** drug such as **celecoxib**, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2003:153473 USPATFULL
TITLE: Finely self-emulsifiable **pharmaceutical** composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105141	A1	20030605
APPLICATION INFO.:	US 2002-119129	A1	20020409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284381P	20010417 (60)
	US 2001-326952P	20011004 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Patent Department, 800 N. Lindbergh Boulevard - 04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
LINE COUNT: 2309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An **orally** deliverable **pharmaceutical** composition is

provided comprising a drug of low water solubility and a solvent liquid that comprises at least one **pharmaceutically** acceptable solvent, at least one **pharmaceutically** acceptable fatty acid and at least one **pharmaceutically** acceptable organic amine, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the fatty acid and the organic amine are present in total and relative amounts such that the composition is finely self-emulsifiable in simulated gastric fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2003:92740 USPATFULL
TITLE:	**Cyclooxygenase-2 inhibitor** compositions having rapid onset of therapeutic effect
INVENTOR(S):	Kararli, Tugrul T., Skokie, IL, UNITED STATES Kontny, Mark J., Libertyville, IL, UNITED STATES Desai, Subhash, Wilmette, IL, UNITED STATES Hageman, Michael J., Portage, MI, UNITED STATES Haskell, Royal J., Kalamazoo, MI, UNITED STATES Hassan, Fred, Peapack, NJ, UNITED STATES Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064098	A1	20030403
APPLICATION INFO.:	US 2001-874504	A1	20010605 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-731350, filed on 6 Dec 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169856P	19991209 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Donald R Holland, Harness Dickey & Pierce, Suite 400, 7700 Bonhomme, Clayton, MO, 63105
NUMBER OF CLAIMS:	58
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	2296

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Pharmaceutical** compositions are provided comprising one or more **orally** deliverable dose units, each comprising a selective **cyclooxygenase-2 inhibitory** drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid **particles**, about 25% to 100% by weight of which are smaller than 1 μm. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have **particular** advantages where rapid onset of therapeutic effect is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2003:65439 USPATFULL
TITLE:	**Pharmaceutical** composition having reduced tendency for drug crystallization
INVENTOR(S):	Gao, Ping, Portage, MI, UNITED STATES Hageman, Michael J., Portage, MI, UNITED STATES Morozowich, Walter, Kalamazoo, MI, UNITED STATES Dalga, Robert J., Kalamazoo, MI, UNITED STATES Stefanski, Kevin J., Kalamazoo, MI, UNITED STATES

Huang, Tiehua, Kalamazoo, MI, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045563	A1	20030306
APPLICATION INFO.:	US 2002-47222	A1	20020115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262555P	20010118 (60)
	US 2001-284608P	20010417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Patent Department, 800 N. Lindbergh Boulevard-04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 91
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 2463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An **orally** deliverable **pharmaceutical** composition is provided comprising a drug of low water solubility, a solvent liquid that comprises at least one **pharmaceutically** acceptable solvent, and a turbidity-decreasing polymer, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the polymer is present in an amount sufficient to substantially inhibit crystallization and/or precipitation of the drug in simulated gastric fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:258478 USPATFULL
TITLE: **Cyclooxygenase-2 inhibitor** compositions having rapid onset of therapeutic effect
INVENTOR(S): Kararli, Tugrul T., Skokie, IL, UNITED STATES
Kontny, Mark J., Libertyville, IL, UNITED STATES
Desai, Subhash, Wilmette, IL, UNITED STATES
Hageman, Michael J., Portage, MI, UNITED STATES
Haskell, Royal J., Kalamazoo, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142045	A1	20021003
APPLICATION INFO.:	US 2002-113157	A1	20020401 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-874504, filed on 5 Jun 2001, PENDING Continuation-in-part of Ser. No. US 31898, PENDING A 371 of International Ser. No. WO 2000-US32434, filed on 6 Dec 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169856P	19991209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HARNESS, DICKEY, & PIERCE, P.L.C, 7700 BONHOMME, STE 400, ST. LOUIS, MO, 63105
NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Pharmaceutical** compositions are provided comprising one or more **orally** deliverable dose units, each comprising a selective **cyclooxygenase-2 inhibitory** drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid **particles**, about 25% to 100% by weight of which are smaller than 1 μm. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have **particular** advantages where rapid onset of therapeutic effect is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:199141 USPATFULL
TITLE: Rapid-onset formulation of a selective **cyclooxygenase-2 inhibitor**
INVENTOR(S): Hariharan, Madhusudan, Evanston, IL, UNITED STATES
Kararli, Tugrul T., Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107250	A1	20020808
APPLICATION INFO.:	US 2001-836905	A1	20010417 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-197746P	20000418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, P.O. Box 5110, Chicago, IL, 60680-5110
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1552
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An **orally** deliverable **pharmaceutical** composition is provided comprising a selective **cyclooxygenase-2 inhibitory** drug of low water solubility, for example **celecoxib**, and a glycol ether, for example diethylene glycol monoethyl ether. At least a substantial part of the drug is in dissolved or solubilized form in a solvent liquid comprising the glycol ether. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders, **particularly** pain. For relief of pain in headache or migraine, the composition can optionally be administered together with a vasodilator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:149172 USPATFULL
TITLE: Selective **cyclooxygenase-2 inhibitors** and vasomodulator compounds for generalized pain and headache pain
INVENTOR(S): Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Skokie, IL, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2002077328	A1	20020620
APPLICATION INFO.:	US 2001-905292	A1	20010713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296196P	20010606 (60)
	US 2001-284248P	20010417 (60)
	US 2000-218101P	20000713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102
NUMBER OF CLAIMS: 125
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A therapeutic combination useful in the treatment, amelioration, prevention, or delay of pain comprising a high energy form of a selective **cyclooxygenase-2 inhibitor**, a vasomodulator, and a **pharmaceutically** acceptable excipient, carrier, or diluent, the **cyclooxygenase-2 inhibitor** and vasomodulator each being present in an amount effective to contribute to the treatment, prevention, ameloriation or delay of pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2002:48047 USPATFULL
TITLE: Use of a **celecoxib** composition for fast pain relief
INVENTOR(S): Karim, Aziz, Skokie, IL, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Gao, Ping, Portage, MI, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002028238	A1	20020307
	US 6579895	B2	20030617
APPLICATION INFO.:	US 2001-866165	A1	20010525 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207729P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HARNESS, DICKEY, & PIERCE, P.L.C, 7700 BONHOMME, STE 400, ST. LOUIS, MO, 63105
NUMBER OF CLAIMS: 118
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a method of rapidly relieving pain in a mammalian, preferably human, subject. The method comprises **orally** administering to the subject an effective pain-relieving amount of a composition comprising **celecoxib** formulated in such a way as to provide, when tested in fasting humans in accordance with standard pharmacokinetic practice, a blood plasma concentration profile of **celecoxib** in which a concentration of about 250 ng/ml is

attained not later than about 30 minutes after **oral** administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 16 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER:	1175214 EUROPATFULL EW 200448 FS PS
TITLE:	**CYCLOOXYGENASE-2 INHIBITOR** COMPOSITIONS HAVING RAPID ONSET OF THERAPEUTIC EFFECT. CYCLOOXYGENASE-2 HEMMER ENTHALTENDE ZUSAMMENSETZUNGEN MIT SCHNELLEM WIRKUNGSEINTRITT. COMPOSITIONS D'INHIBITEUR DE CYCLOOXYGENASE-2 PRODUISANT RAPIDEMENT UN EFFET THERAPEUTIQUE.
INVENTOR(S):	KARARLI, Tugrul, T., 8334 N. Kildare, Skokie, IL 60076, US; KONTNY, Mark, J., 2343 Huntington Lakes Drive, Libertyville, IL 60048, US; DESAI, Subhash, 1011 Greenwood Avenue, Wilmette, IL, US; HAGEMAN, Michael, J., 5262 South 12th Street, Portage, MI 49024, US; HASKELL, Royal, J., Kalamazoo, MI, US
PATENT ASSIGNEE(S):	Pharmacia Corporation, Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680, US
PATENT ASSIGNEE NO:	3214541
AGENT:	Bannerman, David Gardner et al., Withers & Rogers, Goldings House 2 Hays Lane, London SE1 2HW, GB
AGENT NUMBER:	28008
OTHER SOURCE:	MEPB2004054 EP 1175214 B1 0027
SOURCE:	Wila-EPS-2004-H48-T1
DOCUMENT TYPE:	Patent
LANGUAGE:	Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES:	R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR
PATENT INFO.PUB.TYPE:	EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1175214	B1	20041124
'OFFENLEGUNGS' DATE:		20020130
APPLICATION INFO.: EP 2000-980850		20001206
PRIORITY APPLN. INFO.: US 1999-169856		19991208
RELATED DOC. INFO.: WO 00-US32434		001206 INTAKZ
WO 2001041760		010614 INTPNR

REFERENCE PAT. INFO.:	EP 863134	A	WO -32189 A
	WO -53149	A	WO 96-25405 A
	US 5518738	A	US 5552160 A
	US 5756529	A	